Minimal residual disease (MRD) is a state where patients still carry small counts of leukaemic cells during and after therapy. These cells can be the source of future recurrence, and monitoring MRD is essential for therapy adjustments, such as to escalate or decrease therapy doses, to determine...
Phase 3 GMMG-HD7 Trial: Assessing the Impact of Isatuximab on MRD Negativity and PFS in Multiple Myeloma Alana Hippensteele, Managing Editor December 9th 2024 Fixed-Duration Acalabrutinib and Venetoclax Regimens Redefine First-Line Treatment Options for Patients With CLL Alana Hippensteele, Man...
Conference|American Epilepsy Society Annual Meeting In this video filmed at the recently-heldAmerican Epilepsy Society Annual Meeting,Kimford J. Meador, MD, who is a professor at Stanford University School of Medicine, discusses some of the more complications pregnant women with epilepsy may encounter...
Join oncologists nationwide who have learned from the top leaders in the lung cancer field as they share their insights on coronavirus disease 2019 (COVID-19) and how the pandemic is poised to have a significant impact on lung cancer treatment and the health care system.Led by Nathan A....
However, the initial emphasis that has welcomed the production of Dolly the sheep has been progressively quenched in the light of the multitude of developmental defects described in clones [3]. In particular, an emerging insight is that development and function of extra-embryonic membranes is ...
What are the effects of drugs on Treg cells in multiple myeloma, and what are the applications of treg cells in therapy? Introduction Multiple myeloma (MM) is the most common form of plasma cell malignancy, accounting for about 1.7% of all malignant tumors [1]. Although the use of a vari...
immunoPET; multiple myeloma; immunotherapy; precision imaging; companion imaging agents; heterogeneity; theranostic; daratumumab; PD-1/PD-L1; pharmacokinetic1. Introduction Multiple myeloma (MM) is a haematological malignancy characterised by the clonal proliferation of malignant plasma cells within the ...
[5,6], and the 5-year disease-free survival rate of over 80% [3,7,8]. In addition, with molecular monitoring of the minimal residual disease (MRD) assessment [9], physicians’ awareness of early mortality, and effective supportive care, the number of patients with APL who can achieve ...